PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:10
ID: 982853633
FULLTEXT: <td class="diff-addedline"><div>=== Rollout ===</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=982853633
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=982853633&oldid=982679910


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:10
ID: 982853633
FULLTEXT: <td class="diff-addedline"><div>Different vaccines have different shipping and handling requirements. For example, the Pfizer/BioNTech vaccine BNT162 must be shipped and stored at {{Convert|-70|C|F|abbr=}}, must be used within five days of thawing, and has a minimum order of 975 doses, making it unlikely to be rolled out in settings other than large, well-equipped hospitals.&lt;ref&gt;{{Cite web|date=2020-10-09|title=7 looming questions about the rollout of a Covid-19 vaccine|url=https://www.statnews.com/2020/10/09/7-looming-questions-about-the-rollout-of-a-covid-19-vaccine/|access-date=2020-10-10|website=STAT|language=en-US}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=982853633
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=982853633&oldid=982679910


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:14
ID: 982858637
FULLTEXT: <td class="diff-addedline"><div>By August 2020 when only a few vaccine candidates were in Phase III trials many months from establishing safety and efficacy, numerous governments pre-ordered more than two billion doses at a cost of more than US$5 billion.&lt;ref name=unequal/&gt;&lt;ref name=wef-manuf/&gt;&lt;ref&gt;{{cite news |title=Coronavirus vaccine pre-orders worldwide top 5 billion |url=https://www.japantimes.co.jp/news/2020/08/12/world/science-health-world/pre-orders-coronavirus-vaccines/ |accessdate=13 September 2020 |work=The Japan Times |date=12 August 2020}}&lt;/ref&gt; Pre-orders from the UK government for 2021 were for five vaccine doses per person, a number dispiriting organizations like the WHO and GAVI which are promoting fair and equitable access worldwide, especially for developing countries.&lt;ref name=unequal/&gt; In September, CEPI was financially supporting basic and clinical research for nine vaccine candidates, with nine more in evaluation, under financing commitments to manufacture two billion doses of three licensed vaccines by the end of 2021.&lt;ref name=gavi9-4/&gt; Overall before 2022, 7-10 billion COVID-19 vaccine doses may be manufactured worldwide, but the sizable pre-orders by affluent countries – called "vaccine nationalism" – threaten vaccine availability for poorer nations.&lt;ref name=gates2/&gt;&lt;ref name=wef-manuf/&gt;&lt;ref name=unequal/&gt; Brazil and Indonesia <ins class="diffchange diffchange-inline">had</ins> pre-ordered millions of vaccine doses <ins class="diffchange diffchange-inline">that</ins> <ins class="diffchange diffchange-inline">are undergoing phase III trials in their countries The</ins> [[Serum Institute of India]] plans to produce at least one billion vaccine doses, although the Institute has stated that half the doses will be used in India.&lt;ref name=unequal/<ins class="diffchange diffchange-inline">&gt; After joining COVAX in October, China shared that it would produce 600 million vaccine doses before the end of 2020 and another one billion doses in 2021, although it was unsure how many would be for the country's own population of 1.4 billion.&lt;ref&gt;{{Cite web|last=C|first=Hannah|date=2020-10-10|title=China Commits to Producing 600 Million Vaccine Doses by the End of 2020|url=https://www.sciencetimes.com/articles/27653/20201010/china-producing-600-million-vaccine-2020.htm|access-date=2020-10-10|website=Science Times|language=en}}&lt;/ref</ins>&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=982858637
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=982858637&oldid=982853633


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:18
ID: 983355029
FULLTEXT: <td class="diff-addedline"><div>Temporarily paused on October 13 2020 due to an unexplained illness in a participant.&lt;ref&gt;{{Cite we|title=Johnson &amp; Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials|url=https://www.jnj.com/our-company/johnson-johnson-temporarily-pauses-all-dosing-in-our-janssen-covid-19-vaccine-candidate-clinical-trials}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=983355029
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=983355029&oldid=983352748


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:23
ID: 984530064
FULLTEXT: <td class="diff-addedline"><div>Strategies are being considered for fast-tracking the licensing of a vaccine against COVID‑19, especially by compressing (to a few months) the usually lengthy duration of Phase{{nbsp}}II–III trials (typically many years).&lt;ref name="eyal"&gt;{{Cite journal|last1=Eyal|first1=Nir|last2=Lipsitch|first2=Marc|last3=Smith|first3=Peter G.|title=Human challenge studies to accelerate coronavirus vaccine licensure|url=https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa152/5814216|journal=The Journal of Infectious Diseases|doi=10.1093/infdis/jiaa152|date=31 March 2020|volume=221|issue=11|pages=1752–56|pmid=32232474|pmc=7184325|name-list-style=vanc|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200424095527/https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa152/5814216|archive-date=24 April 2020|url-status=live}}&lt;/ref&gt;&lt;ref name="callaway"&gt;{{Cite journal|vauthors=Callaway E|date=April 2020|title=Should scientists infect healthy people with the coronavirus to test vaccines?|url=https://www.nature.com/articles/d41586-020-00927-3|journal=Nature|volume=580|issue=7801|page=17|doi=10.1038/d41586-020-00927-3|pmid=32218549|bibcode=2020Natur.580...17C|doi-access=free|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200414035045/https://www.nature.com/articles/d41586-020-00927-3|archive-date=14 April 2020|url-status=live}}&lt;/ref&gt;&lt;ref name="boodman"&gt;{{Cite web|url=https://www.statnews.com/2020/03/11/researchers-rush-to-start-moderna-coronavirus-vaccine-trial-without-usual-animal-testing/|title=Coronavirus vaccine clinical trial starting without usual animal data|publisher=STAT|first=Eric | last=Boodman |date=13 March 2020|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200417060301/https://www.statnews.com/2020/03/11/researchers-rush-to-start-moderna-coronavirus-vaccine-trial-without-usual-animal-testing/|archive-date=17 April 2020|url-status=live| name-list-style=vanc }}&lt;/ref&gt; [[Human challenge study|Challenge studies]] have been implemented previously for diseases less deadly than COVID‑19 infection, such as common influenza, [[typhoid fever]], [[cholera]], and [[malaria]].&lt;ref name=callaway/&gt;&lt;ref name=cohen/&gt; Following preliminary proof of safety and efficacy of a candidate vaccine in laboratory animals and healthy humans, controlled challenge studies might be implemented to bypass typical Phase{{nbsp}}III research, providing an accelerated path to license a COVID‑19 vaccine.&lt;ref name="eyal" /&gt;&lt;ref name="cohen"&gt;{{Cite journal|url=https://www.sciencemag.org/news/2020/03/speed-coronavirus-vaccine-testing-deliberately-infecting-volunteers-not-so-fast-some|title=Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn|last=Cohen|first=Jon|date=31 March 2020|journal=Science|doi=10.1126/science.abc0006|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200414031310/https://www.sciencemag.org/news/2020/03/speed-coronavirus-vaccine-testing-deliberately-infecting-volunteers-not-so-fast-some|archive-date=14 April 2020|url-status=live | name-list-style = vanc }}&lt;/ref&gt;&lt;ref name=callaway/&gt;<ins class="diffchange diffchange-inline"> Beginning in January 2021, dozens of young adult volunteers will be deliberately infected with COVID-19 in a challenge trial conducted in a [[London, England|London]] hospital under management by the UK government COVID-19 Vaccine Taskforce.&lt;ref name="call-challenge"&gt;{{cite journal |author1=Ewen Callaway |title=Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials |journal=Nature |date=20 October 2020 |doi=10.1038/d41586-020-02821-4 |url=https://www.nature.com/articles/d41586-020-02821-4}}&lt;/ref&gt; Once an infection dose of COVID-19 is identified, two or more of the candidate COVID-19 vaccines will be tested for effectiveness in preventing infection.&lt;ref name=call-challenge/&gt; </ins></div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=984530064
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=984530064&oldid=984528753


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:27
ID: 985103748
FULLTEXT: <td class="diff-addedline"><div><a name="movedpara_3_0_rhs"></a>|-</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985103748
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985103748&oldid=985102850


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:27
ID: 985103748
FULLTEXT: <td class="diff-addedline"><div><a name="movedpara_3_1_rhs"></a>|'''BNT162 a1, b1, b2, c2'''&lt;wbr /&gt;{{efn-la|Four vaccines}}&lt;ref name="NCT04368728"&gt;{{cite web |title=Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Adults |url=https://clinicaltrials.gov/ct2/show/NCT04368728 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04368728 |date=30 April 2020 |access-date=14 July 2020}}&lt;/ref&gt;&lt;ref name="EudraCT-2020-001038-36"&gt;{{cite web |title=A Multi-site Phase I/II, 2-Part, Dose-Escalation Trial Investigating the Safety and Immunogenicity of four Prophylactic SARS-CoV-2 RNA Vaccines Against COVID-19 Using Different Dosing Regimens in Healthy Adults |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE |website=EU Clinical Trials Register |publisher=European Union |type=Registry |id=[[EudraCT]] 2020-001038-36 |date=14 April 2020 |access-date=22 April 2020 |archive-url=https://web.archive.org/web/20200422111024/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001038-36/DE |archive-date=22 April 2020 |url-status=live}}&lt;/ref&gt;&lt;br /&gt;[[BioNTech]], [[Fosun Pharma]], [[Pfizer]]</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985103748
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985103748&oldid=985102850


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:27
ID: 985103748
FULLTEXT: <td class="diff-addedline"><div><a name="movedpara_3_2_rhs"></a>|[[RNA vaccine|mRNA]]</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985103748
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985103748&oldid=985102850


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:27
ID: 985103748
FULLTEXT: <td class="diff-addedline"><div><a name="movedpara_3_3_rhs"></a>|{{ClinicalStudyInfo|align=left|phase=3|participants=30000|description=Randomized, placebo-controlled|references=&lt;ref&gt;{{cite news |last=Lovelace Jr. |first=Berkeley |date=27 July 2020 |title=Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday |url=https://www.cnbc.com/2020/07/27/pfizer-and-biontech-began-late-stage-human-trial-for-coronavirus-vaccine-monday.html |work=[[CNBC]] |access-date=3 August 2020 | name-list-style = vanc }}&lt;/ref&gt;}}</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985103748
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985103748&oldid=985102850


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:27
ID: 985103748
FULLTEXT: <td class="diff-addedline"><div>|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=45|description=[[Preprint]]. Strong RBD-binding [[Immunoglobulin G|IgG]] and [[neutralizing antibody]] response peaked 7 days after a [[booster dose]], robust CD4+ and CD8+ [[T cell]] responses, undetermined durability. '''Adverse effects''': dose-dependent and moderate including pain at the injection site, fatigue, headache, chills, muscle and join pain, fever&lt;ref&gt;{{cite journal |last1=Mulligan |first1=Mark |last2=Lyke |first2=Kirsten |last3=Kitchin |first3=Nicholas |last4=Absalon |first4=Judith |last5=Gurtman |first5=Alejandra |last6=Lockhart |first6=Stephen |last7=Neuzil |first7=Kathleen |last8=Raabe |first8=Vanessa |last9=Bailey |first9=Ruth |last10=Swanson |first10=Kena |last11=Li |first11=Ping |last12=Koury |first12=Kenneth |last13=Kalina |first13=Warren |last14=Cooper |first14=David |last15=Fonter-Garfias |first15=Camila |last16=Shi |first16=Pei-Yong |last17=Tuereci |first17=Ozlem |last18=Tompkins |first18=Kristin |last19=Walsh |first19=Edward |last20=Frenck |first20=Robert |last21=Falsey |first21=Ann |last22=Dormitzer |first22=Philip |last23=Gruber |first23=William |last24=Sahin |first24=Ugur |last25=Jansen |first25=Kathrin |s2cid=220266992 |display-authors=6 |date=1 July 2020 |title=Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report |url=https://www.medrxiv.org/content/10.1101/2020.06.30.20142570v1.full.pdf |journal=MedRxiv |type=[[Preprint]] |doi=10.1101/2020.06.30.20142570 |access-date=3 August 2020 | name-list-style = vanc }}&lt;/ref&gt;&lt;ref&gt;{{cite journal | last1=Sahin | first1=Ugur | last2=Muik | first2=Alexander | last3=Derhovanessian | first3=Evelyna | last4=Vogler | first4=Isabel | last5=Kranz | first5=Lena M | last6=Vormehr | first6=Mathias | last7=Baum | first7=Alina | last8=Pascal | first8=Kristen | last9=Quandt | first9=Jasmin | last10=Maurus | first10=Daniel | last11=Brachtendorf | first11=Sebastian | last12=Loerks | first12=Verena L | last13=Sikorski | first13=Julian | last14=Hilker | first14=Rolf | last15=Becker | first15=Dirk | last16=Eller | first16=Ann-Kathrin | last17=Gruetzner | first17=Jan | last18=Boesler | first18=Carsten | last19=Rosenbaum | first19=Corinna | last20=Kuehnle | first20=Marie-Cristine | last21=Luxemburger | first21=Ulrich | last22=Kemmer-Brueck | first22=Alexandra | last23=Langer | first23=David | last24=Bexon | first24=Martin | last25=Bolte | first25=Stefanie | last26=Kariko | first26=Katalin | last27=Palanche | first27=Tania | last28=Fischer | first28=Boris | last29=Schultz | first29=Armin | last30=Shi | first30=Pei-Yong | last31=Fontes-Garfias | first31=Camila | last32=Perez | first32=John L | last33=Swanson | first33=Kena A | last34=Loschko | first34=Jakob | last35=Scully | first35=Ingrid L | last36=Cutler | first36=Mark | last37=Kalina | first37=Warren | last38=Kyratsous | first38=Christos A | last39=Cooper | first39=David | last40=Dormitzer | first40=Philip R | last41=Jansen | first41=Kathrin U | last42=Tuereci | first42=Oezlem | display-authors=6 | title=Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine | journal = MedRxiv | year=2020 |type=[[Preprint]] | doi=10.1101/2020.07.17.20140533 | doi-access=free | url=https://www.medrxiv.org/content/10.1101/2020.07.17.20140533v1.full.pdf | lay-url=https://blogs.sciencemag.org/pipeline/archives/2020/07/20/more-pfizer-phase-i-results-antibodies-viral-mutations-and-t-cells | name-list-style = vanc }}&lt;/ref&gt;}}</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985103748
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985103748&oldid=985102850


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:27
ID: 985103748
FULLTEXT: <td class="diff-addedline"><div><a name="movedpara_3_5_rhs"></a>|62 in the US, Germany</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985103748
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985103748&oldid=985102850


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:27
ID: 985103748
FULLTEXT: <td class="diff-addedline"><div><a name="movedpara_3_6_rhs"></a>| data-sort-value="2021-05" |Apr 2020{{snd}}May 2021</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985103748
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985103748&oldid=985102850


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:31
ID: 985479328
FULLTEXT: <td class="diff-addedline"><div>Some countries choose to buy vaccines licensed by reputable national organizations, such as EMA, FDA, or national agencies in other<ins class="diffchange diffchange-inline"> affluent countries, but such purchases typically are more expensive and may not have distribution resources suitable to local conditions in developing countries.&lt;ref name=who-vacc/&gt;</ins></div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985479328
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985479328&oldid=985478714


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:31
ID: 985479328
FULLTEXT: <td class="diff-addedline"><div>=== Australia ===</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985479328
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985479328&oldid=985478714


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:31
ID: 985479328
FULLTEXT: <td class="diff-addedline"><div>In October 2020, the Australian [[Therapeutic Goods Administration]] (TGA) granted provisional determinations to AstraZeneca Pty Ltd in relation to its COVID-19 vaccine, ChAd0x1-S [recombinant] and to Pfizer Australia Pty Ltd in relation to its COVID-19 vaccine, BNT162b2 [mRNA].&lt;ref&gt;{{cite web | title=TGA grants provisional determination for COVID-19 vaccine | website=[[Therapeutic Goods Administration]] (TGA) | date=9 October 2020 | url=https://www.tga.gov.au/tga-grants-provisional-determination-covid-19-vaccine | access-date=25 October 2020}}&lt;/ref&gt;&lt;ref&gt;{{cite web | title=TGA grants second provisional determination for a COVID-19 vaccine | website=[[Therapeutic Goods Administration]] (TGA) | date=14 October 2020 | url=https://www.tga.gov.au/tga-grants-second-provisional-determination-covid-19-vaccine | access-date=25 October 2020}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985479328
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985479328&oldid=985478714


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:31
ID: 985479328
FULLTEXT: <td class="diff-addedline"><div>As of August 2020<ins class="diffchange diffchange-inline">,</ins> in the United States, there is no national strategy for how a successful vaccine will be ethically prioritized or distributed to vulnerable population segments, such as [[Homelessness in the United States|homeless]] and [[Incarceration in the United States|incarcerated people]] and the elderly.&lt;ref name=malik/&gt;&lt;ref name=toner/&gt;&lt;ref name="corey"&gt;{{cite journal | last1=Corey | first1=Lawrence | last2=Mascola | first2=John R | last3=Fauci | first3=Anthony S | last4=Collins | first4=Francis S | title=A strategic approach to COVID-19 vaccine R&amp;D | journal=Science| volume=368 | issue=6494 | date=2020-05-11 | issn=0036-8075 | doi=10.1126/science.abc5312 | pages=948–50| pmid=32393526 |url=https://science.sciencemag.org/content/368/6494/948.long| doi-access=free }}&lt;/ref&gt; After licensure, monitoring of the vaccine and its production, including periodic inspections for GMP compliance, continue as long as the manufacturer retains its license, which may include additional submissions to the FDA of tests for potency, safety, and purity for each vaccine manufacturing step.&lt;ref name=fda-vacc/&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985479328
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985479328&oldid=985478714


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:36
ID: 985484532
FULLTEXT: <td class="diff-addedline"><div>|{{ClinicalStudyInfo|align=left|phase=3|participants=30000|description=Interventional; [[randomized controlled trial|randomized, placebo-controlled study]] for efficacy, safety, and immunogenicity.&lt;ref name="NCT04516746"&gt;{{cite web |title=A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04516746 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04383574 |date=12 May 2020 |access-date=26 August 2020}}&lt;/ref&gt;}} Brazil (5,000)&lt;ref&gt;{{cite web |title=Trial of Oxford COVID-19 vaccine starts in Brazil |url=https://covid19vaccinetrial.co.uk/brazil-trial-launch |publisher=[[Jenner Institute]] |access-date=26 August 2020}}&lt;/ref&gt; International enrolment of the Phase III trial was paused on 8 September 2020, due to an adverse neurological event in one participant,&lt;ref name="phillips "&gt;{{cite journal | last1=Phillips | first1=Nicky | last2=Cyranoski | first2=David | last3=Mallapaty | first3=Smriti | title=A leading coronavirus vaccine trial is on hold: scientists react | journal=Nature | date=2020-09-09 | issn=0028-0836 | doi=10.1038/d41586-020-02594-w | pmid=32908295 | s2cid=221620587 |url=https://www.nature.com/articles/d41586-020-02594-w}}&lt;/ref&gt;&lt;ref&gt;{{cite web |author1=Adam Feuerstein |title=Covid-19 vaccine trial participant had serious neurological symptoms, but could be discharged today, AstraZeneca CEO says |url=https://www.statnews.com/2020/09/09/astrazeneca-covid19-vaccine-trial-hold-patient-report/ |publisher=STAT |accessdate=2020-09-10 |date=2020-09-09}}&lt;/ref&gt;<ins class="diffchange diffchange-inline">&lt;ref&gt;{{cite</ins> <ins class="diffchange diffchange-inline">news</ins> <ins class="diffchange diffchange-inline">|</ins> <ins class="diffchange diffchange-inline">title=AstraZeneca</ins> <ins class="diffchange diffchange-inline">Pauses</ins> <ins class="diffchange diffchange-inline">Vaccine</ins> <ins class="diffchange diffchange-inline">Trial</ins> <ins class="diffchange diffchange-inline">for</ins> <ins class="diffchange diffchange-inline">Safety</ins> <ins class="diffchange diffchange-inline">Review</ins> <ins class="diffchange diffchange-inline">|</ins> <ins class="diffchange diffchange-inline">website=[[The</ins> <ins class="diffchange diffchange-inline">New</ins> <ins class="diffchange diffchange-inline">York</ins> <ins class="diffchange diffchange-inline">Times]]</ins> <ins class="diffchange diffchange-inline">|</ins> <ins class="diffchange diffchange-inline">date=9 September 2020 | url=https://www.nytimes.com/2020/09/08/health/coronavirus-astrazeneca-</ins>vaccine<ins class="diffchange diffchange-inline">-safety</ins>.<ins class="diffchange diffchange-inline">html | access-date=25 October 2020 | authors=Katherine J. Wu, Katie Thomas}}&lt;/ref&gt;</ins>&lt;ref&gt;{{<ins class="diffchange diffchange-inline">cite</ins> news |<ins class="diffchange diffchange-inline"> title=Safety Review Begins Into AstraZeneca's Coronavirus Vaccine Trial | website=[[The New York Times]] | date=10 September 2020 | </ins>url=https://<ins class="diffchange diffchange-inline">www</ins>.<ins class="diffchange diffchange-inline">nytimes.com</ins>/<ins class="diffchange diffchange-inline">2020</ins>/<ins class="diffchange diffchange-inline">09/10/health/covid</ins>-astrazeneca-<ins class="diffchange diffchange-inline">vaccine</ins>-<ins class="diffchange diffchange-inline">trans.html | access</ins>-<ins class="diffchange diffchange-inline">date=25 October 2020 | first=Katherine J. | last=Wu | name</ins>-<ins class="diffchange diffchange-inline">list</ins>-<ins class="diffchange diffchange-inline">style=vanc }}&lt;/ref&gt; but resumed on 12 September in the UK</ins>.<ins class="diffchange diffchange-inline">&lt;ref&gt;{{cite news</ins> |<ins class="diffchange diffchange-inline"> </ins>title=AstraZeneca <ins class="diffchange diffchange-inline">Partly</ins> <ins class="diffchange diffchange-inline">Resumes</ins> <ins class="diffchange diffchange-inline">Coronavirus</ins> <ins class="diffchange diffchange-inline">Vaccine</ins> <ins class="diffchange diffchange-inline">Trial After Halting It for Safety</ins> |<ins class="diffchange diffchange-inline"> website</ins>=[[<ins class="diffchange diffchange-inline">The</ins> <ins class="diffchange diffchange-inline">New</ins> <ins class="diffchange diffchange-inline">York Times</ins>]] |<ins class="diffchange diffchange-inline"> </ins>date=12 September 2020 |<ins class="diffchange diffchange-inline"> url</ins>=<ins class="diffchange diffchange-inline">https://www.nytimes.com/2020/09/</ins>12<ins class="diffchange diffchange-inline">/health/astrazeneca-coronavirus-vaccine-trial-resumes.html</ins> <ins class="diffchange diffchange-inline">| access-date=25 October</ins> 2020 |<ins class="diffchange diffchange-inline"> authors</ins>=<ins class="diffchange diffchange-inline">Carl Zimmer, Katie Thomas, Benjamin Mueller</ins>}}&lt;/ref<ins class="diffchange diffchange-inline">&gt; On 23 October, AstraZeneca said it will resume the trial in the US.&lt;ref name="NYT 20201023" /</ins>&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985484532
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985484532&oldid=985480641


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:36
ID: 985484532
FULLTEXT: <td class="diff-addedline"><div>| data-sort-value="2022-10" |<ins class="diffchange diffchange-inline">July</ins> 2020{{snd}}<ins class="diffchange diffchange-inline">October</ins> 2022</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985484532
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985484532&oldid=985480641


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:36
ID: 985484532
FULLTEXT: <td class="diff-addedline"><div>Temporarily paused on 13 October 2020, due to an unexplained illness in a participant.&lt;ref&gt;{{cite news | title=Johnson &amp; Johnson pauses its coronavirus vaccine trial because of a volunteer's 'unexplained illness.' | website=[[The New York Times]] | date=13 October 2020 | url=https://www.nytimes.com/2020/10/12/world/johnson-johnson-pauses-its-coronavirus-vaccine-trial-because-of-a-volunteers-unexplained-illness.html | access-date=25 October 2020 | authors=Virginia Hughes, Katie Thomas, Carl Zimmer, Katherine J. Wu}}&lt;/ref&gt;&lt;ref&gt;{{cite news | url=https://www.wsj.com/articles/johnson-johnson-pauses-covid-19-vaccine-trials-due-to-sick-subject-11602555101 | title=Johnson &amp; Johnson Pauses Covid-19 Vaccine Trials Due to Sick Subject | work=[[The Wall Street Journal]] | first1=Peter | last1=Loftus | date=13 October 2020 | name-list-style=vanc }}&lt;/ref&gt;&lt;ref&gt;{{cite web|title=Johnson &amp; Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials|url=https://www.jnj.com/our-company/johnson-johnson-temporarily-pauses-all-dosing-in-our-janssen-covid-19-vaccine-candidate-clinical-trials}}&lt;/ref&gt;&lt;ref&gt;{{cite news | url=https://www.washingtonpost.com/health/2020/10/13/covid-vaccine-trial-pause/ | title=Johnson &amp; Johnson, Eli Lilly pause covid-19 trials for possible safety issues | work=[[The Washington Post]] | date=13 October 2020 | | first=Carolyn Y. | last=Johnson | name-list-style=vanc }}&lt;/ref&gt; Johnson &amp; Johnson announced, on 23 October, that they are preparing to resume the trial in the US.&lt;ref&gt;{{cite news | url=https://www.wsj.com/articles/covid-19-vaccine-trial-from-astrazeneca-oxford-can-resume-in-u-s-11603476923 | title=Pivotal Studies of Covid-19 Vaccines From AstraZeneca, J&amp;J Resuming | work=[[The Wall Street Journal]] | first1=Thomas M. | last1=Burton | first2=Peter | last2=Loftus | date=23 October 2020 | name-list-style=vanc }}&lt;/ref&gt;&lt;ref&gt;{{cite news | url=https://www.washingtonpost.com/health/2020/10/23/jj-vaccine-trial-to-resume/ | title=Johnson &amp; Johnson, AstraZeneca coronavirus vaccine trials set to resume | work=[[The Washington Post]] | date=24 October 2020 | | first=Carolyn Y. | last=Johnson | name-list-style=vanc }}&lt;/ref&gt;&lt;ref name="NYT 20201023"&gt;{{cite news | title=Two Companies Restart Virus Trials in U.S. After Safety Pauses | website=[[The New York Times]] | date=23 October 2020 | url=https://www.nytimes.com/2020/10/23/health/covid-vaccine-astrazeneca-johnson-and-johnson.html | access-date=25 October 2020 | authors=Katherine J. Wu, Carl Zimmer, Sharon LaFraniere, Noah Weiland }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985484532
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985484532&oldid=985480641


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>&lt;noinclude&gt;A '''COVID‑19 vaccine''' is any of several different [[vaccine]]s intended to  provide [[acquired immunity]] against [[coronavirus disease 2019]] (COVID‑19).&lt;/noinclude&gt; Previous work to develop a vaccine against &lt;noinclude&gt;the coronavirus diseases [[Severe acute respiratory syndrome|SARS]]&lt;/noinclude&gt;&lt;includeonly&gt;SARS&lt;/includeonly&gt; and [[Middle East respiratory syndrome|MERS]] established knowledge about the structure and function of coronaviruses{{snd}}which accelerated development during early 2020 of varied technology platforms for a COVID‑19 vaccine.&lt;ref name="diamond"&gt;{{Cite journal|title=The challenges of vaccine development against a new virus during a pandemic|first1=Michael S|last1=Diamond|first2=Theodore C|last2=Pierson|date=2020-05-13|journal=Cell Host and Microbe|volume=27|issue=5|pages=699–703|doi=10.1016/j.chom.2020.04.021|pmc=7219397|pmid=32407708 | name-list-style = vanc }}&lt;/ref&gt; As of October 2020, there were 321 vaccine candidates in development, a 2.5 fold increase since April. However, no candidate has completed [[Vaccine trial|vaccine trials]] to prove its safety and efficacy.&lt;ref name="thanh2"&gt;{{cite journal | last1=Le | first1=Tung Thanh | last2=Cramer | first2=Jakob P. | last3=Chen | first3=Robert | last4=Mayhew | first4=Stephen | title=Evolution of the COVID-19 vaccine development landscape | journal=Nature Reviews Drug Discovery |date=2020-09-04 | volume=19 | issue=10 | pages=667–68 | issn=1474-1776 | doi=10.1038/d41573-020-00151-8 | pmid=32887942 | s2cid=221503034 |<ins class="diffchange diffchange-inline">doi-access</ins>=<ins class="diffchange diffchange-inline">free | name</ins>-<ins class="diffchange diffchange-inline">list</ins>-<ins class="diffchange diffchange-inline">style=vanc </ins>}}&lt;/ref&gt; In October, some 44 vaccine candidates were in [[clinical research]]: namely 34 in [[Phases of clinical research#Phase II|Phase I–II trials]] and 10 in [[Phases of clinical research#Phase III|Phase II–III trials]].&lt;ref name="thanh2" /&gt;&lt;ref name="london"&gt;{{cite web|url=https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/|title=COVID-19 vaccine development pipeline (Refresh URL to update)|publisher=Vaccine Centre, London School of Hygiene and Tropical Medicine|date=2020-09-14|access-date=2020-09-17}}&lt;/ref&gt;&lt;ref name="milken"&gt;{{cite web|title=COVID-19 vaccine tracker (Choose vaccines tab, apply filters to view select data)|url=https://airtable.com/shrSAi6t5WFwqo3GM/tblEzPQS5fnc0FHYR/viwDBH7b6FjmIBX5x?blocks=hide|publisher=Milken Institute|access-date=2020-09-16|date=2020-09-17|lay-url=https://milkeninstitute.org/covid-19-tracker}}&lt;/ref&gt;&lt;ref name="who-tracker"&gt;{{Cite web|title=Draft landscape of COVID 19 candidate vaccines|url=https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-vaccines|publisher=World Health Organization|date=2020-09-17|access-date=2020-09-17}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>The [[World Health Organization]] (WHO), the [[Coalition for Epidemic Preparedness Innovations]] (CEPI), and the [[Gates Foundation]] (GF) are committing money and organizational resources for the prospect that several vaccines will be needed to prevent continuing COVID‑19 infection.&lt;ref name=gates2/&gt; The CEPI, which is organizing a {{US$|2}}{{nbsp}}billion worldwide fund for rapid investment and development of vaccine candidates,&lt;ref name="cepi-fund"&gt;{{cite web |title=CEPI welcomes UK Government's funding and highlights need for $2 billion to develop a vaccine against COVID-19 |url=https://cepi.net/news_cepi/2-billion-required-to-develop-a-vaccine-against-the-covid-19-virus/ |publisher=Coalition for Epidemic Preparedness Innovations, Oslo, Norway |access-date=23 March 2020 |date=6 March 2020 |archive-url=https://web.archive.org/web/20200322170547/https://cepi.net/news_cepi/2-billion-required-to-develop-a-vaccine-against-the-covid-19-virus/ |archive-date=22 March 2020 |url-status=live }}&lt;/ref&gt; indicated in September that clinical data to support licensure may be available by the end of 2020.&lt;ref name=thanh2/&gt; On 4{{nbsp}}May 2020, the WHO organized a [[telethon]] which received {{US$|8}}.1{{nbsp}}billion in pledges from forty countries to support rapid development of vaccines to prevent COVID‑19 infections.&lt;ref name="waked"&gt;{{Cite web|title=EU spearheads $8 billion virus fundraiser |url=https://finance.yahoo.com/news/eu-hosts-virus-telethon-seeking-first-7-5-003500556.html|publisher=Yahoo Finance|first=Damon | last=Wake |date=2020-05-04|access-date=2020-05-04 | archiveurl = https://web.archive.org/web/20200629033556if_/https://finance.yahoo.com/news/eu-hosts-virus-telethon-seeking-first-7-5-003500556.html | archivedate = 2020-06-29 | url-status = live<ins class="diffchange diffchange-inline"> | name-list-style=vanc</ins> }}&lt;/ref&gt; At the same time, the WHO also announced the deployment of an international "Solidarity trial" for simultaneous evaluation of several vaccine candidates reaching [[Phases of clinical research#Phase II|Phase II–III clinical trials]].&lt;ref name="who-accel"&gt;{{Cite web|title=Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine|url=https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine|publisher=World Health Organization|date=2020-04-27|access-date=2020-05-02|quote=It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. [The] WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.|archive-url=https://web.archive.org/web/20200430185550/https://www.who.int/emergencies/diseases/novel-coronavirus-2019/global-research-on-novel-coronavirus-2019-ncov/solidarity-trial-accelerating-a-safe-and-effective-covid-19-vaccine|archive-date=30 April 2020|url-status=live}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>A vaccine for an infectious disease has never before been produced in less than several years, and no vaccine exists for preventing a [[coronavirus]] infection in humans.&lt;ref name="gates2"&gt;{{Cite web|title=The vaccine race explained: What you need to know about the COVID-19 vaccine|url=https://www.gatesnotes.com/Health/What-you-need-to-know-about-the-COVID-19-vaccine|last=Gates|first=Bill|publisher=The Gates Notes|date=2020-04-30|access-date=2020-05-02|archive-url=https://web.archive.org/web/20200514010012/https://www.gatesnotes.com/Health/What-you-need-to-know-about-the-COVID-19-vaccine|archive-date=14 May 2020|url-status=live | name-list-style = vanc }}&lt;/ref&gt; After the coronavirus was detected in December 2019,&lt;ref name="who-time"&gt;{{Cite web|title=World Health Organization timeline – COVID-19|url=https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19|publisher=World Health Organization|date=2020-04-27|access-date=2020-05-02|archive-url=https://web.archive.org/web/20200429012212/https://www.who.int/news-room/detail/27-04-2020-who-timeline---covid-19|archive-date=29 April 2020|url-status=live}}&lt;/ref&gt; the [[Nucleic acid sequence|genetic sequence]] of COVID‑19 was published on 11 January 2020, triggering an urgent international response to prepare for an outbreak and hasten development of a preventive vaccine.&lt;ref name="thanh"&gt;{{cite journal | last1=Thanh Le | first1=Tung | last2=Andreadakis | first2=Zacharias | last3=Kumar | first3=Arun | last4=Gómez Román | first4=Raúl | last5=Tollefsen | first5=Stig | last6=Saville | first6=Melanie | last7=Mayhew | first7=Stephen | display-authors=6 | title=The COVID-19 vaccine development landscape | journal=Nature Reviews Drug Discovery | date=9 April 2020 | volume=19 | issue=5 | pages=305–06 | issn=1474-1776 | doi=10.1038/d41573-020-00073-5 | pmid=32273591 | url=https://www.nature.com/articles/d41573-020-00073-5 | doi-access=free | <ins class="diffchange diffchange-inline">name</ins>-<ins class="diffchange diffchange-inline">list</ins>-<ins class="diffchange diffchange-inline">style</ins>=<ins class="diffchange diffchange-inline">vanc</ins> }}&lt;/ref&gt;&lt;ref name="gates1"&gt;{{cite journal | vauthors = Gates B | title = Responding to Covid-19: A once-in-a-century pandemic? | journal = The New England Journal of Medicine | date = February 2020 | volume = 382 | issue = 18 | pages = 1677–79 | pmid = 32109012 | doi = 10.1056/nejmp2003762 | doi-access = free }}&lt;/ref&gt;&lt;ref name="Fauci"&gt;{{cite journal | vauthors = Fauci AS, Lane HC, Redfield RR | title = Covid-19: Navigating the uncharted | journal = The New England Journal of Medicine | volume = 382 | issue = 13 | pages = 1268–69 | date = March 2020 | pmid = 32109011 | doi = 10.1056/nejme2002387 | pmc = 7121221 }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>By April 2020, "almost 80 companies and institutes in 19 countries" were working on this virtual gold rush.&lt;ref name="cssa"&gt;{{cite news |last1=Schmidt |first1=Charles |title=Genetic Engineering Could Make a COVID-19 Vaccine in Months Rather Than Years |url=https://www.scientificamerican.com/article/genetic-engineering-could-make-a-covid-19-vaccine-in-months-rather-than-years1/ |publisher=Scientific American |date=1 June 2020<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt; Also in April, CEPI estimated that as many as six of the vaccine candidates against COVID‑19 should be chosen by international coalitions for development through Phase{{nbsp}}II–III trials, and three should be streamlined through regulatory and quality assurance for eventual licensing at a total cost of at least {{US$|2}}{{nbsp}}billion.&lt;ref name=thanh2/&gt;&lt;ref name=yamey/&gt;&lt;ref name=gates2/&gt; Another analysis estimates 10 candidates will need simultaneous initial development, before a select few are chosen for the final path to licensing.&lt;ref name=gates2/&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>CEPI is working with international health authorities and vaccine developers to create another {{US$|2}}{{nbsp}}billion fund in a global partnership between public, private, philanthropic, and civil society organizations for accelerated research and clinical testing of eight vaccine candidates, with the 2020–21 goal of supporting several candidates for full development to licensing.&lt;ref name=thanh2/&gt;&lt;ref name=yamey/&gt;&lt;ref name="cepi-landmark"&gt;{{Cite web|title=Landmark global collaboration launched to defeat COVID-19 pandemic|url=https://cepi.net/news_cepi/landmark-global-collaboration-launched-to-defeat-covid-19-pandemic/|publisher=CEPI|date=2020-04-24|access-date=2020-05-02|quote=The global nature of a pandemic means that any vaccine or medicine that is successfully developed will be needed immediately all over the world. That means that the challenge we face is not only one of R&amp;D but one of manufacturing at scale, and equitable access.|archive-url=https://web.archive.org/web/20200502023137/https://cepi.net/news_cepi/landmark-global-collaboration-launched-to-defeat-covid-19-pandemic/|archive-date=2 May 2020|url-status=live}}&lt;/ref&gt; The United Kingdom, Canada, Belgium, Norway, Switzerland, Germany and the Netherlands had already donated {{US$|915}}{{nbsp}}million to CEPI by early May.&lt;ref name=waked/&gt;&lt;ref name="reuters"&gt;{{Cite news|date=2020-04-27|title=Special Report: Countries, companies risk billions in race for coronavirus vaccine|first1 = Julie | last1 = Steenhuysen |first2 = Peter | last2 = Eisler |first3 = Allison | last3 = Martell |first4 = Stephanie | last4 = Nebehay |work=Reuters|url=https://www.reuters.com/article/health-coronavirus-vaccine-idUSL2N2CF0JG|access-date=2020-05-02|archive-url=https://web.archive.org/web/20200515031817/https://www.reuters.com/article/health-coronavirus-vaccine-idUSL2N2CF0JG|archive-date=15 May 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt; The [[Bill &amp; Melinda Gates Foundation]] (Gates Foundation), a private [[charitable organization]] dedicated to vaccine research and distribution, is donating {{US$|250}}{{nbsp}}million in support of CEPI for research and public educational support on COVID‑19 vaccines.&lt;ref name="sanger"&gt;{{Cite news|last1=Sanger|first1=David E.|last2=Kirkpatrick|first2=David D.|last3=Zimmer|first3=Carl|last4=Thomas|first4=Katie|last5=Wee|first5=Sui-Lee|date=2020-05-02|title=With Pressure Growing, Global Race for a Vaccine Intensifies|work=[[The New York Times]]|url=https://www.nytimes.com/2020/05/02/us/politics/vaccines-coronavirus-research.html|access-date=2020-05-02|issn=0362-4331|archive-url=https://web.archive.org/web/20200511003506/https://www.nytimes.com/2020/05/02/us/politics/vaccines-coronavirus-research.html|archive-date=11 May 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;&lt;ref&gt;{{Cite news|title=Bill Gates thinks there are 8 to 10 promising coronavirus vaccine candidates and one could be ready in as little as 9 months|url=https://www.businessinsider.com/bill-gates-10-promising-coronavirus-vaccine-candidates-2020-5|last=Hamilton|first=Isobel Asher|date=2020-05-01|work=Business Insider|access-date=2020-05-02|archive-url=https://web.archive.org/web/20200516101559/https://www.businessinsider.com/bill-gates-10-promising-coronavirus-vaccine-candidates-2020-5|archive-date=16 May 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>National governments dedicating resources for national or international investments in vaccine research, development, and manufacturing beginning in 2020, included the [[Government of Canada|Canadian government]] which announced {{CAD|275}}{{nbsp}}million in funding for 96 research vaccine research projects at Canadian companies and universities, with plans to establish a "vaccine bank" of several new vaccines that could be used if another coronavirus outbreak occurs.&lt;ref name="abedi"&gt;{{cite news |first=Maham |last=Abedi |title=Canada to spend $192M on developing COVID-19 vaccine |url=https://globalnews.ca/news/6717883/coronavirus-canada-vaccine-spending/ |access-date=24 March 2020 |work=Global News |date=23 March 2020 |archive-url=https://web.archive.org/web/20200409200638/https://globalnews.ca/news/6717883/coronavirus-canada-vaccine-spending/ |archive-date=9 April 2020 |url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc</ins> }}&lt;/ref&gt;&lt;ref name="can-funding"&gt;{{cite web |title=Government of Canada funds 49 additional COVID-19 research projects – Details of the funded projects |url=https://www.canada.ca/en/institutes-health-research/news/2020/03/government-of-canada-funds-49-additional-covid-19-research-projects-details-of-the-funded-projects.html |publisher=Government of Canada |access-date=23 March 2020 |date=23 March 2020 |archive-url=https://web.archive.org/web/20200322163807/https://www.canada.ca/en/institutes-health-research/news/2020/03/government-of-canada-funds-49-additional-covid-19-research-projects-details-of-the-funded-projects.html |archive-date=22 March 2020 |url-status=live }}&lt;/ref&gt; A further investment of {{CAD|1.1}}{{nbsp}}billion was added to support clinical trials in Canada and develop manufacturing and supply chains for vaccines.&lt;ref name="can-research"&gt;{{Cite web|title=Government of Canada's research response to COVID-19|url=https://www.canada.ca/en/public-health/services/publications/diseases-conditions/covid-19-government-canada-research-response.html|publisher=Government of Canada|date=2020-04-23|access-date=2020-05-04|archive-url=https://web.archive.org/web/20200513135919/https://www.canada.ca/en/public-health/services/publications/diseases-conditions/covid-19-government-canada-research-response.html|archive-date=13 May 2020|url-status=live}}&lt;/ref&gt; On 4{{nbsp}}May, the Canadian government committed {{CAD|850}}{{nbsp}}million to the WHO's live streaming effort to raise {{US$|8}}{{nbsp}}billion for COVID‑19 vaccines and preparedness.&lt;ref name="aiello"&gt;{{Cite news|title='A global challenge': PM Trudeau commits $850 million to global fight against COVID-19|url=https://www.ctvnews.ca/health/coronavirus/a-global-challenge-pm-trudeau-commits-850-million-to-global-fight-against-covid-19-1.4923565|last=Aiello|first=Rachel|date=2020-05-04|work=CTV News|access-date=2020-05-04|archive-url=https://web.archive.org/web/20200510070903/https://www.ctvnews.ca/health/coronavirus/a-global-challenge-pm-trudeau-commits-850-million-to-global-fight-against-covid-19-1.4923565|archive-date=10 May 2020|url-status=live | name-list-style = vanc }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>In [[China]], the [[Government of China|government]] is providing low-rate loans to a vaccine developer through its [[People's Bank of China|central bank]], and has "quickly made land available for the company" to build production plants.&lt;ref name=reuters/&gt; As of June 2020, six of the eleven COVID‑19 vaccine candidates in early-stage human testing were developed by Chinese organizations.&lt;ref name=sanger/&gt; Three Chinese vaccine companies and research institutes are supported by the government for financing research, conducting clinical trials, and manufacturing the most promising vaccine candidates, while prioritizing rapid evidence of efficacy over safety.&lt;ref name="takada"&gt;{{Cite news|title=US and China unleash wallets in race for coronavirus vaccine|last1=Takada|first1=Noriyuki|last2=Satake|first2=Minoru|url=https://asia.nikkei.com/Spotlight/Coronavirus/US-and-China-unleash-wallets-in-race-for-coronavirus-vaccine|work=Nikkei Asian Review|date=2020-05-02|access-date=2020-05-03|archive-url=https://web.archive.org/web/20200510111134/https://asia.nikkei.com/Spotlight/Coronavirus/US-and-China-unleash-wallets-in-race-for-coronavirus-vaccine|archive-date=10 May 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt; On 18 May, China had pledged {{USD|2}}{{nbsp}}billion to support overall efforts by the WHO for programs against COVID‑19.&lt;ref&gt;{{Cite news|title=China's Xi announces $2B for coronavirus response as WHO faces calls for investigation|url=https://www.nbcnews.com/news/world/coronavirus-who-faces-global-call-investigation-general-assembly-n1209061|work=NBC News|authors=Yuliya Talmazan, Keir Simmons, Laura Saravia|date=2020-05-18|access-date=2020-05-18|archive-url=https://web.archive.org/web/20200518171737/https://www.nbcnews.com/news/world/coronavirus-who-faces-global-call-investigation-general-assembly-n1209061|archive-date=18 May 2020|url-status=live}}&lt;/ref&gt; On 22 July, China additionally announced that it plans to provide a US$1 billion loan to make its vaccine accessible for countries in [[Latin America]] and the [[Caribbean]].&lt;ref&gt;{{cite news |last1=Ore |first1=Diego |title=Mexico says China plans $1 billion loan to ease Latam access to virus vaccine |url=https://www.reuters.com/article/us-health-coronavirus-mexico-china/mexico-says-china-plans-1-billion-loan-to-ease-latam-access-to-virus-vaccine-idUSKCN24O08L |accessdate=16 August 2020 |work=Reuters |date=23 July 2020<ins class="diffchange diffchange-inline"> | name-list-style=vanc</ins> }}&lt;/ref&gt; On 24 August, [[Premier of the People's Republic of China|Chinese Premier]] [[Li Keqiang]] announced it would provide five Southeast Asian countries of Cambodia, Laos, Myanmar, Thailand and Vietnam priority access to the vaccine once it was fully developed.&lt;ref&gt;{{Cite web|date=2020-08-24|title=China promises Mekong neighbours access to Chinese Covid-19 vaccine|url=https://www.scmp.com/news/china/diplomacy/article/3098610/china-promises-its-mekong-neighbours-priority-access|access-date=2020-08-24|website=South China Morning Post}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>In April, the UK government formed a COVID‑19 vaccine [[task force]] to stimulate British efforts for rapidly developing a vaccine through collaborations of industry, universities, and government agencies across the vaccine development pipeline, including clinical trial placement at UK hospitals, regulations for approval, and eventual manufacturing.&lt;ref name="morriss"&gt;{{Cite web|title=Government launches coronavirus vaccine taskforce as human clinical trials start|url=https://pharmafield.co.uk/pharma_news/government-launches-coronavirus-vaccine-taskforce-as-human-clinical-trials-start/|last=Morriss|first=Emma|publisher=Pharmafield|date=2020-04-22|access-date=2020-05-03 | name-list-style = vanc }}&lt;/ref&gt; The vaccine development initiatives at the University of Oxford and [[Imperial College London|Imperial College of London]] were financed with {{GBP|44}}{{nbsp}}million in April.&lt;ref name="gartner"&gt;{{Cite news|last1=Gartner|first1=Annelies|last2=Roberts|first2=Lizzie|date=2020-05-03|title=How close are we to a coronavirus vaccine? Latest news on UK trials|work=The Telegraph|url=https://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-vaccine-uk-trials-news-latest-update-covid-19/|access-date=2020-05-03|issn=0307-1235|archive-url=https://web.archive.org/web/20200504203335/https://www.telegraph.co.uk/global-health/science-and-disease/coronavirus-vaccine-uk-trials-news-latest-update-covid-19/|archive-date=4 May 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;&lt;ref name="oxford"&gt;{{Cite web|title=Landmark partnership announced for development of COVID-19 vaccine|publisher=University of Oxford|url=http://www.ox.ac.uk/news/2020-04-30-landmark-partnership-announced-development-covid-19-vaccine|date=2020-04-30|access-date=2020-05-03|archive-url=https://web.archive.org/web/20200513010438/http://www.ox.ac.uk/news/2020-04-30-landmark-partnership-announced-development-covid-19-vaccine|archive-date=13 May 2020|url-status=live}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>The United States [[Biomedical Advanced Research and Development Authority]] (BARDA), a federal agency that funds disease-fighting technology, announced investments of nearly {{US$|1}}{{nbsp}}billion to support American COVID‑19 vaccine development, and preparation for manufacturing the most promising candidates. On 16 April, BARDA made a {{US$|483}}{{nbsp}}million investment in the vaccine developer, [[Moderna]] and its partner, [[Johnson &amp; Johnson]].&lt;ref name=reuters/&gt;&lt;ref name="kuznia"&gt;{{Cite news|title=In quest for vaccine, US makes 'big bet' on company with unproven technology|url=https://www.cnn.com/2020/05/01/us/coronavirus-moderna-vaccine-invs/index.html|last1=Kuznia|first1=Robert|last2=Polglase|first2=Katie|date=2020-05-01|work=CNN|access-date=2020-05-02|last3=Mezzofiore|first3=Gianluca|archive-url=https://web.archive.org/web/20200513005730/https://www.cnn.com/2020/05/01/us/coronavirus-moderna-vaccine-invs/index.html|archive-date=13 May 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt; BARDA has an additional {{US$|4}}{{nbsp}}billion to spend on vaccine development, and will have roles in other American investment for development of six to eight vaccine candidates to be in clinical studies over 2020–21 by companies such as [[Sanofi Pasteur]] and [[Regeneron]].&lt;ref name=kuznia/&gt;&lt;ref name="lee"&gt;{{Cite web|title=Health officials eyeing at least one of 14 potential coronavirus vaccines to fast-track|url=https://www.nbcnews.com/politics/white-house/health-officials-eyeing-least-one-14-potential-coronavirus-vaccines-fast-n1198326|work=NBC News|last1=Lee|first1=Carol E|last2=Welker|first2=Kristen|first3=Elyse|last3=Perlmutter-Gumbiner|date=2020-05-01|access-date=2020-05-02|archive-url=https://web.archive.org/web/20200511104127/https://www.nbcnews.com/politics/white-house/health-officials-eyeing-least-one-14-potential-coronavirus-vaccines-fast-n1198326|archive-date=11 May 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt; On 15 May, the US government announced federal funding for a fast-track program called [[Operation Warp Speed]], which has the goals of placing diverse vaccine candidates in clinical trials by the fall of 2020, and manufacturing 300{{nbsp}}million doses of a licensed vaccine by January 2021. The project chief advisor is [[Moncef Slaoui]] and its [[Chief Operating Officer]] is Army General [[Gustave F. Perna|Gustave Perna]].&lt;ref&gt;{{Cite journal|last=Cohen|first=Jon|date=2020-05-15|title=U.S. 'Warp Speed' vaccine effort comes out of the shadows|url=https://science.sciencemag.org/content/368/6492/692|journal=Science|volume=368|issue=6492|pages=692–93|doi=10.1126/science.368.6492.692|issn=0036-8075|pmid=32409451|bibcode=2020Sci...368..692C|doi-access=free|access-date=15 May 2020|archive-url=https://web.archive.org/web/20200519111116/https://science.sciencemag.org/content/368/6492/692|archive-date=19 May 2020|url-status=live | name-list-style = vanc }}&lt;/ref&gt;&lt;ref&gt;{{Cite news|authors=Justin Sink, Jordan Fabian, Riley Griffin|date=2020-05-15|title=Trump introduces 'Warp Speed' leaders to hasten COVID-19 vaccine|work=Bloomberg|url=https://www.bloomberg.com/news/articles/2020-05-15/trump-to-introduce-warp-speed-leaders-after-vaccine-criticism|access-date=2020-05-15|archive-url=https://web.archive.org/web/20200521231515/https://www.bloomberg.com/news/articles/2020-05-15/trump-to-introduce-warp-speed-leaders-after-vaccine-criticism|archive-date=21 May 2020|url-status=live}}&lt;/ref&gt; In June, the Warp Speed team said it would work with seven companies developing COVID‑19 vaccine candidates: [[Moderna]], [[Johnson &amp; Johnson Pharmaceutical Research and Development|Johnson &amp; Johnson]], [[Merck &amp; Co.|Merck]], [[Pfizer]], and the [[University of Oxford]] in collaboration with [[AstraZeneca]], as well as two others.&lt;ref&gt;{{Cite news|authors=Riley Griffith, Jennifer Jacobs|title=White House Works With Seven Drugmakers in 'Warp Speed' Push|url=https://www.bloomberg.com/news/articles/2020-06-03/white-house-working-with-seven-drugmakers-in-warp-speed-push|access-date=2020-06-04|work=Bloomberg|date=2020-06-03|archive-url=https://web.archive.org/web/20200603220008/https://www.bloomberg.com/news/articles/2020-06-03/white-house-working-with-seven-drugmakers-in-warp-speed-push|archive-date=3 June 2020|url-status=live}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>[[Geopolitics|Geopolitical]] issues, safety concerns for vulnerable populations, and manufacturing challenges for producing billions of doses are compressing schedules to shorten the standard vaccine development timeline, in some cases combining clinical trial steps over months, a process typically conducted sequentially over years.&lt;ref name=sanger/&gt; As an example, Chinese vaccine developers and the government [[Chinese Center for Disease Control and Prevention]] began their efforts in January 2020,&lt;ref&gt;{{cite news|last1=Jeong-ho|first1=Lee |last2=Zheng|first2=William|last3=Zhou|first3=Laura | url= https://www.scmp.com/news/china/society/article/3047676/number-coronavirus-cases-china-doubles-spread-rate-accelerates |title=Chinese scientists race to develop vaccine as coronavirus death toll jumps|date=26 January 2020|work=[[South China Morning Post]]|access-date=28 January 2020 |url-status=live |archive-url= https://web.archive.org/web/20200126073453/https://www.scmp.com/news/china/society/article/3047676/number-coronavirus-cases-china-doubles-spread-rate-accelerates |archive-date=26 January 2020<ins class="diffchange diffchange-inline"> | name-list-style=vanc</ins> }}&lt;/ref&gt; and by March were pursuing numerous candidates on short timelines, with the goal to showcase Chinese technology strengths over those of the United States, and to reassure the Chinese people about the quality of vaccines produced in China.&lt;ref name=sanger/&gt;&lt;ref name="wee"&gt;{{Cite news|last=Wee|first=Sui-Lee|date=2020-05-04|title=China's coronavirus vaccine drive empowers a troubled industry|work=[[The New York Times]]|url=https://www.nytimes.com/2020/05/04/business/coronavirus-china-vaccine.html|access-date=2020-05-04|issn=0362-4331|archive-url=https://web.archive.org/web/20200504175312/https://www.nytimes.com/2020/05/04/business/coronavirus-china-vaccine.html|archive-date=4 May 2020|url-status=live | name-list-style = vanc }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>As the pandemic expands during 2020, research at universities is obstructed by [[Social distancing|physical distancing]] and closing of laboratories.&lt;ref&gt;{{Cite news|title=COVID-19 vaccine researchers say pandemic lockdown placing many serious obstacles to their work|url=https://nationalpost.com/news/covid-19-vaccine-researchers-say-pandemic-lockdown-placing-many-serious-obstacles-to-their-work|first=Tom | last=Blackwell |work=National Post|date=2020-04-20|access-date=2020-05-03| name-list-style=vanc }}&lt;/ref&gt;&lt;ref&gt;{{Cite web|title=Covid-19 has shuttered labs. It could put a generation of researchers at risk|url=https://www.statnews.com/2020/05/04/coronavirus-lab-shutdowns-impact-on-scientists-research-delays/|date=2020-05-04|<ins class="diffchange diffchange-inline">work</ins>=<ins class="diffchange diffchange-inline">[[Stat (website)|Stat]]</ins>|first=Justin | last=Chen |access-date=2020-05-04|archive-url=https://web.archive.org/web/20200506072301/https://www.statnews.com/2020/05/04/coronavirus-lab-shutdowns-impact-on-scientists-research-delays/|archive-date=6 May 2020|url-status=live| name-list-style=vanc }}&lt;/ref&gt; Globally, supplies critical to vaccine research and development are increasingly scarce due to international competition or national [[Sequestration (law)|sequestration]].&lt;ref name=takada/&gt; Timelines for conducting clinical research{{snd}}normally a sequential process requiring years{{snd}}are being compressed into safety, efficacy, and dosing trials running simultaneously over months, potentially compromising safety assurance.&lt;ref name=reuters/&gt;&lt;ref name=sanger/&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|'''AZD1222'''&lt;wbr/&gt;{{efn-la|Oxford name: ''ChAdOx1{{nbsp}}nCoV-19''. Manufacturing in Brazil to be carried out by [[Oswaldo Cruz Foundation]].&lt;ref&gt;{{cite news |last1=Walsh |first1=Nick |last2=Shelley |first2=Jo |last3=Duwe |first3=Eduardo |last4=Bonnett |first4=William |date=27 July 2020 |title=The world's hopes for a coronavirus vaccine may run in these health care workers' veins |url=https://edition.cnn.com/2020/07/27/americas/brazil-covid-19-sinovac-vaccine-intl/index.html |work=[[CNN]] |location=[[São Paulo]] |access-date=3 August 2020 | name-list-style = vanc }}&lt;/ref&gt;}}&lt;ref name="NCT04400838"&gt;{{cite web |title=Investigating a Vaccine Against COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04400838 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04400838 |date=26 May 2020 |access-date=14 July 2020}}&lt;/ref&gt;&lt;ref name="EudraCT-2020-001228-32"&gt;{{cite web |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001228-32/GB |title=A Phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 |website=EU Clinical Trials Register |publisher=European Union |type=Registry |id=[[EudraCT]] 2020-001228-32 |date=21 April 2020 |access-date=3 August 2020}}&lt;/ref&gt;&lt;ref name="ISRCTN89951424"&gt;{{cite journal |url=http://www.isrctn.com/ISRCTN89951424 |title=A Phase III study to investigate a vaccine against COVID-19 |website=ISRCTN |type=Registry |id=ISRCTN89951424 |doi=10.1186/ISRCTN89951424 |date=26 May 2020 |access-date=3 August 2020|last1=O'Reilly |first1=Peter | name-list-style = vanc }}&lt;/ref&gt;&lt;br /&gt;[[University of Oxford]], [[AstraZeneca]]</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|{{ClinicalStudyInfo|align=left|phase=3|participants=30000|description=Interventional; [[randomized controlled trial|randomized, placebo-controlled study]] for efficacy, safety, and immunogenicity.&lt;ref name="NCT04516746"&gt;{{cite web |title=A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19 |url=https://clinicaltrials.gov/ct2/show/NCT04516746 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04383574 |date=12 May 2020 |access-date=26 August 2020}}&lt;/ref&gt;}} Brazil (5,000)&lt;ref&gt;{{cite web |title=Trial of Oxford COVID-19 vaccine starts in Brazil |url=https://covid19vaccinetrial.co.uk/brazil-trial-launch |publisher=[[Jenner Institute]] |access-date=26 August 2020}}&lt;/ref&gt; International enrolment of the Phase III trial was paused on 8 September 2020, due to an adverse neurological event in one participant,&lt;ref name="phillips "&gt;{{cite journal | last1=Phillips | first1=Nicky | last2=Cyranoski | first2=David | last3=Mallapaty | first3=Smriti | title=A leading coronavirus vaccine trial is on hold: scientists react | journal=Nature | date=2020-09-09 | issn=0028-0836 | doi=10.1038/d41586-020-02594-w | pmid=32908295 | s2cid=221620587 |url=https://www.nature.com/articles/d41586-020-02594-w<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;&lt;ref&gt;{{cite web |author1=Adam Feuerstein |title=Covid-19 vaccine trial participant had serious neurological symptoms, but could be discharged today, AstraZeneca CEO says |url=https://www.statnews.com/2020/09/09/astrazeneca-covid19-vaccine-trial-hold-patient-report/ |<ins class="diffchange diffchange-inline">work</ins>=<ins class="diffchange diffchange-inline">[[Stat (website)|Stat]]</ins> |accessdate=2020-09-10 |date=2020-09-09}}&lt;/ref&gt;&lt;ref&gt;{{cite news | title=AstraZeneca Pauses Vaccine Trial for Safety Review | website=[[The New York Times]] | date=9 September 2020 | url=https://www.nytimes.com/2020/09/08/health/coronavirus-astrazeneca-vaccine-safety.html | access-date=25 October 2020 | authors=Katherine J. Wu, Katie Thomas}}&lt;/ref&gt;&lt;ref&gt;{{cite news | title=Safety Review Begins Into AstraZeneca's Coronavirus Vaccine Trial | website=[[The New York Times]] | date=10 September 2020 | url=https://www.nytimes.com/2020/09/10/health/covid-astrazeneca-vaccine-trans.html | access-date=25 October 2020 | first=Katherine J. | last=Wu | name-list-style=vanc }}&lt;/ref&gt; but resumed on 12 September in the UK.&lt;ref&gt;{{cite news | title=AstraZeneca Partly Resumes Coronavirus Vaccine Trial After Halting It for Safety | website=[[The New York Times]] | date=12 September 2020 | url=https://www.nytimes.com/2020/09/12/health/astrazeneca-coronavirus-vaccine-trial-resumes.html | access-date=25 October 2020 | authors=Carl Zimmer, Katie Thomas, Benjamin Mueller}}&lt;/ref&gt; On 23 October, AstraZeneca said it will resume the trial in the US.&lt;ref name="NYT 20201023" /&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|{{ClinicalStudyInfo|align=left|phase=3|participants=40,000|description=global multi-center, randomized, double-blind, placebo-controlled to evaluate efficacy, safety and immunogenicity&lt;ref&gt;{{cite web |last1=Gou |first1=Jinbo |title=Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above |url=https://clinicaltrials.gov/ct2/show/NCT04526990 |publisher=clinicaltrials.gov |accessdate=17 September 2020<ins class="diffchange diffchange-inline"> | name-list-style=vanc</ins> }}&lt;/ref&gt;}}</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=45|description=Strong RBD-binding [[Immunoglobulin G|IgG]] and [[neutralizing antibody]] response peaked 7 days after a [[booster dose]], robust CD4+ and CD8+ [[T cell]] responses, undetermined durability. '''Adverse effects''': dose-dependent and moderate including pain at the injection site, fatigue, headache, chills, muscle and join pain, fever&lt;ref&gt;{{cite web |last1=Mulligan |first1=Mark J. |last2=Lyke |first2=Kirsten E. |last3=Kitchin |first3=Nicholas |last4=Absalon |first4=Judith |last5=Gurtman |first5=Alejandra |last6=Lockhart |first6=Stephen |last7=Neuzil |first7=Kathleen |last8=Raabe |first8=Vanessa |last9=Bailey |first9=Ruth |last10=Swanson |first10=Kena A. |last11=Li |first11=Ping |last12=Koury |first12=Kenneth |last13=Kalina |first13=Warren |last14=Cooper |first14=David |last15=Fontes-Garfias |first15=Camila |last16=Shi |first16=Pei-Yong |last17=Türeci |first17=Özlem |last18=Tompkins |first18=Kristin R. |last19=Walsh |first19=Edward E. |last20=Frenck |first20=Robert |last21=Falsey |first21=Ann R. |last22=Dormitzer |first22=Philip R. |last23=Gruber |first23=William C. |last24=Şahin |first24=Uğur |last25=Jansen |first25=Kathrin U. |title=Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults |url=https://doi.org/10.1038/s41586-020-2639-4 |website=Nature |pages=589–593 |doi=10.1038/s41586-020-2639-4 |date=October 2020<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;}}</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|''Unnamed''&lt;wbr /&gt;&lt;ref name="ChiCTR2000034780"&gt;{{cite journal |last1=Chen |first1=Wei |last2=Al Kaabi |first2=Nawal |title=A Phase III clinical trial for inactivated novel coronavirus pneumonia (COVID-19) vaccine (Vero cells) |journal=Chinese Clinical Trial Registry |date=18 July 2020 |url=http://www.chictr.org.cn/showprojen.aspx?proj=56651 |accessdate=15 August 2020<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;&lt;br /&gt;[[China National Pharmaceutical Group|Sinopharm]]: Beijing Institute of Biological Products, Wuhan Institute of Biological Products</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|{{ClinicalStudyInfo|align=left|phase=3|participants=48000|description=Randomized, double-blind, parallel placebo-controlled, to evaluate safety and protective efficacy in the [[United Arab Emirates]], [[Bahrain]], [[Jordan]],&lt;ref&gt;{{cite web |last1=Yang |first1=Yunkai |title=A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above |url=https://clinicaltrials.gov/ct2/show/NCT04510207 |website=clinicaltrials.gov |publisher=Clinical Trials |accessdate=15 September 2020<ins class="diffchange diffchange-inline"> | name-list-style=vanc</ins> }}&lt;/ref&gt; and [[Argentina]]&lt;ref&gt;{{cite web |title=Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19) |url=https://clinicaltrials.gov/ct2/show/NCT04560881?term=vaccine&amp;cond=covid-19&amp;draw=2&amp;rank=3 |website=clinicaltrials.gov |accessdate=28 September 2020 }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>On 14 September, UAE approved Sinopharm's vaccine for emergency use by front-line healthcare workers following successful interim results in the Phase III trials.&lt;ref name="UAE approval"&gt;{{cite web |last1=Maxwell |first1=Chris |title=Coronavirus: UAE authorises emergency use of vaccine for frontline workers |url=https://www.thenational.ae/uae/health/coronavirus-uae-authorises-emergency-use-of-vaccine-for-frontline-workers-1.1077680 |publisher=The National |accessdate=14 September 2020<ins class="diffchange diffchange-inline"> | name-list-style=vanc</ins> }}&lt;/ref&gt;}}</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|{{ClinicalStudyInfo|align=left|phase=1|endphase=2|participants=76}} [[Neutralizing antibody]] and [[T cell]] responses. '''Adverse effects''': pain at injection site, fever, headache, weakness, and muscle/joint pain&lt;ref name="logunov"&gt;{{cite journal | last1=Logunov | first1=Denis Y | last2=Dolzhikova | first2=Inna V | last3= others | title=Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia | journal=The Lancet | year=2020 | volume=396 | issue=10255 | pages=887–97 | issn=0140-6736 | doi=10.1016/s0140-6736(20)31866-3 | pmid=32896291 | s2cid=221472251 |url=https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext| doi-access=free<ins class="diffchange diffchange-inline"> | name-list-style=vanc</ins> }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|'''[[CoronaVac]]'''&lt;ref name="NCT04383574"&gt;{{cite web |title=Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection (COVID-19) (Renqiu) |url=https://clinicaltrials.gov/ct2/show/NCT04383574 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04383574 |date=12 May 2020 |access-date=14 July 2020}}&lt;/ref&gt;&lt;ref name="NCname= nct04456595="&gt;{{cite web |url=https://clinicaltrials.gov/ct2/show/NCT04456595 |title=Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals (PROFISCOV) |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04456595 |date=2 July 2020 |access-date=3 August 2020}}&lt;/ref&gt;&lt;ref&gt;{{cite journal |last1=PT. Bio Farma |title=A Phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-COV-2 inactivated vaccine in healthy adults aged 18–59 years in Indonesia |journal=Registri Penyakit Indonesia |date=10 August 2020 |url=https://www.ina-registry.org/index.php?act=registry_trial_detail&amp;code_trial=16202009080721WXFM0YX |accessdate=15 August 2020<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;&lt;br /&gt;[[Sinovac Biotech|Sinovac]]</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|2 in China; 12 in Brazil; Bandung, Indonesia&lt;ref&gt;{{Cite web|last=Indonesia|first=C. N. N.|title=Fakta Terbaru Uji Klinis Vaksin Covid-19 di Bandung|url=https://www.cnnindonesia.com/teknologi/20200805023946-199-532230/fakta-terbaru-uji-klinis-vaksin-covid-19-di-bandung|access-date=2020-08-26|website=teknologi|language=id-ID<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|'''Ad26.COV2.S'''&lt;ref&gt;{{Cite web|title=A Study of Ad26.COV2.S in Adults|url=https://clinicaltrials.gov/ct2/show/NCT04436276|access-date=2020-08-23|publisher=ClinicalTrials.gov, US National Library of Medicine|date=2020-08-04}}&lt;/ref&gt;&lt;ref&gt;{{Cite report|last1=Sadoff|first1=Jerry|last2=Le Gars|first2=Mathieu|last3=Shukarev|first3=Georgi|last4=Heerwegh|first4=Dirk|last5=Truyers|first5=Carla|last6=de Groot|first6=Anna Marit|last7=Stoop|first7=Jeroen|last8=Tete|first8=Sarah|last9=Van Damme|first9=Wim|last10=Leroux-Roels|first10=Isabel|last11=Berghmans|first11=Pieter-Jan|date=2020-09-25|title=Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial|url=http://medrxiv.org/lookup/doi/10.1101/2020.09.23.20199604|doi=10.1101/2020.09.23.20199604|s2cid=221882008|access-date=27 September 2020|type=none<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;&lt;ref&gt;{{Cite web|last=|first=|date=|title=A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants|url=https://clinicaltrials.gov/ct2/show/NCT04505722|url-status=live|archive-url=|archive-date=|access-date=|website=ClinicalTrials.gov|publisher=US National Library of Medicine<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|{{ClinicalStudyInfo|align=left|phase=1|participants=131|description=[[Preprint]]. [[Immunoglobulin G|IgG]] and [[neutralizing antibody]] response with adjuvant after [[booster dose]]. '''Adverse effects''': short-duration, low grade, local pain, headache, fatigue, [[myalgia|myalgia]]&lt;ref&gt;{{cite journal |last1=Keech |first1=Cheryl |last2=Albert |first2=Gary |last3=Reed |first3=Patricia |last4=Neal |first4=Susan |last5=Plested |first5=Joyce |last6=Zhu |first6=Mingzhu |last7=Cloney-Clark |first7=Shane |last8=Zhou |first8=Haixia |last9=Patel |first9=Nita |last10=Frieman |first10=Matthew |last11=Haupt |first11=Robert |last12=Logue |first12=James |last13=McGrath |first13=Marisa |last14=Weston |first14=Stuart |last15=Piedra |first15=Pedro |last16=Cho |first16=Iksung |last17=Robertson |first17=Andreana |last18=Desai |first18=Chinar |last19=Callahan |first19=Kathleen |last20=Lewis |first20=Maggie |last21=Price-Abbott |first21=Patricia |last22=Formica |first22=Neil |last23=Shinde |first23=Vivek |last24=Fries |first24=Louis |last25=Linkliter |first25=Jason |last26=Griffin |first26=Paul |last27=Wilkinson |first27=Bethanie |last28=Smith |first28=Gale |last29=Glenn |first29=Gregory |s2cid=221004959 |display-authors=6 |date=6 August 2020 |title=First-in-Human Trial of a SARS CoV 2 Recombinant Spike Protein Nanoparticle Vaccine |url=https://www.medrxiv.org/content/10.1101/2020.08.05.20168435v1.full.pdf |journal=MedRxiv |type=[[Preprint]] |doi=10.1101/2020.08.05.20168435 |access-date=7 August 2020<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;|name-list-format=vanc}}</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>|'''LNP-nCoVsaRNA'''&lt;wbr/&gt;&lt;ref name="ISRCTN17072692"&gt;{{cite journal |title=Clinical trial to assess the safety of a coronavirus vaccine in healthy men and women |url=https://www.isrctn.com/ISRCTN17072692 |website=ISRCTN |type=Registry |id=ISRCTN17072692 |doi=10.1186/ISRCTN17072692 |date=22 May 2020 |access-date=8 June 2020|last1=Ward |first1=Denise |last2=McCormack |first2=Sheena <ins class="diffchange diffchange-inline">| doi-access=free</ins> | name-list-style=vanc }}&lt;/ref&gt;&lt;br /&gt;[[Medical Research Council (United Kingdom)|MRC]] [[clinical trials unit]] at [[Imperial College London]]</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>Assertions have been made that COVID‑19 mortality has been lower in countries having routine [[BCG vaccine]] administered against tuberculosis,&lt;ref name="deVrieze-April"&gt;{{cite journal |last1=de Vrieze |first1=Jop |s2cid=216359131 |title=Can a century-old TB vaccine steel the immune system against the new coronavirus? |journal=Science |date=23 March 2020 |doi=10.1126/science.abb8297 | name-list-style = vanc }}&lt;/ref&gt;&lt;ref&gt;{{cite journal |vauthors=O'Neill LA, Netea MG |title=BCG-induced trained immunity: can it offer protection against COVID-19? |journal=Nat. Rev. Immunol. |volume=20 |issue=6 |pages=335–37 |date=June 2020 |pmid=32393823 |pmc=7212510 |doi=10.1038/s41577-020-0337-y }}&lt;/ref&gt;&lt;ref&gt;{{cite journal |vauthors=Escobar LE, Molina-Cruz A, Barillas-Mury C |title=BCG vaccine protection from severe coronavirus disease 2019 (COVID-19) |journal=Proc. Natl. Acad. Sci. U.S.A. |volume= 117|issue= 30|pages= 17720–26|date=July 2020 |pmid=32647056 |doi=10.1073/pnas.2008410117 |pmc=7395502 }}&lt;/ref&gt;&lt;ref&gt;{{cite journal |vauthors=Koti M, Morales A, Graham CH, Siemens DR |title=BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy |journal=J Immunother Cancer |volume=8 |issue=2 |page= e001119|date=July 2020 |pmid=32636240 |pmc=7342862 |doi=10.1136/jitc-2020-001119 }}&lt;/ref&gt; though the [[World Health Organization]] (WHO) has said there is no evidence that this vaccine is effective against the COVID‑19 virus.&lt;ref&gt;{{cite web | title=Bacille Calmette-Guérin (BCG) vaccination and COVID-19 | website=[[World Health Organization]] (WHO) | date=12 April 2020 | url=https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19 | access-date=1 May 2020 | archive-url=https://web.archive.org/web/20200430121126/https://www.who.int/news-room/commentaries/detail/bacille-calmette-gu%C3%A9rin-(bcg)-vaccination-and-covid-19 | archive-date=30 April 2020 | url-status=live }}&lt;/ref&gt; In March 2020, a randomized trial of BCG vaccine to reduce COVID‑19 illness began in the Netherlands, seeking to recruit 1,000 healthcare workers.&lt;ref name="EudraCT-2020-000919-69"&gt;{{cite web |title=Reducing health care workers absenteeism in SARS-CoV-2 pandemic by enhanced trained immune responses through Bacillus Calmette-Guérin vaccination, a randomized controlled trial (COVID-19) |url=https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL |website=EU Clinical Trials Register |publisher=European Union |type=Registry |id=[[EudraCT]] 2020-000919-69 |date=17 March 2020 |access-date=11 April 2020 |archive-url=https://web.archive.org/web/20200404104902/https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-000919-69/NL |archive-date=4 April 2020 |url-status=live}}&lt;/ref&gt; A further randomized trial in Australia is seeking to enroll 4,170 healthcare workers.&lt;ref name="MCRI-BCG-trial"&gt;{{cite web |title=Murdoch Children's Research Institute to trial preventative vaccine for COVID-19 healthcare workers |url=https://www.mcri.edu.au/news/murdoch-children%E2%80%99s-research-institute-trial-preventative-vaccine-covid-19-healthcare-workers |website=Murdoch Children's Research Institute |access-date=11 April 2020 |archive-url=https://web.archive.org/web/20200413230625/https://www.mcri.edu.au/news/murdoch-children%2525E2%252580%252599s-research-institute-trial-preventative-vaccine-covid-19-healthcare-workers |archive-date=13 April 2020 |url-status=live }}&lt;/ref&gt;&lt;ref name="NCT04327206"&gt;{{cite web |title=BCG Vaccination to Protect Healthcare Workers Against COVID-19 (BRACE) |url=https://clinicaltrials.gov/ct2/show/NCT04327206 |website=[[ClinicalTrials.gov]] |publisher=[[United States National Library of Medicine]] |type=Registry |id=NCT04327206 |date=31 March 2020 |access-date=11 April 2020 |archive-url=https://web.archive.org/web/20200411045454/https://clinicaltrials.gov/ct2/show/NCT04327206 |archive-date=11 April 2020 |url-status=live}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>In September 2020, eleven of the vaccine candidates in clinical development used adjuvants to enhance immunogenicity.&lt;ref name=thanh2/&gt; An [[immunological adjuvant]] is a substance formulated with a vaccine to elevate the immune response to an [[antigen]], such as the COVID‑19 virus or influenza virus.&lt;ref name="tregoning"&gt;{{cite journal | last1=Tregoning | first1=John S. | last2=Russell | first2=Ryan F. | last3=Kinnear | first3=Ekaterina | title=Adjuvanted influenza vaccines | journal=Human Vaccines and Immunotherapeutics| volume=14 | issue=3 | date=2018-01-25 | issn=2164-5515 | pmid=29232151 | pmc=5861793 | doi=10.1080/21645515.2017.1415684 | pages=550–64<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt; Specifically, an adjuvant may be used in formulating a COVID‑19 vaccine candidate to boost its immunogenicity and efficacy to reduce or prevent COVID-19 infection in vaccinated individuals.&lt;ref name=tregoning/&gt;&lt;ref name="wang"&gt;{{cite journal | last1=Wang | first1=Jieliang | last2=Peng | first2=Ying | last3=Xu | first3=Haiyue | last4=Cui | first4=Zhengrong | last5=Williams | first5=Robert O. | title=The COVID-19 vaccine race: Challenges and opportunities in vaccine formulation | journal=AAPS PharmSciTech| volume=21 | issue=6 | date=2020-08-05 | page=225 | issn=1530-9932 | pmid=32761294 | pmc=7405756 | doi=10.1208/s12249-020-01744-7<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt; Adjuvants used in COVID‑19 vaccine formulation may be particularly effective for technologies using the inactivated COVID-19 virus and recombinant protein-based or vector-based vaccines.&lt;ref name=wang/&gt; [[Aluminium|Aluminum salts]], known as "alum", were the first adjuvant used for licensed vaccines, and are the adjuvant of choice in some 80% of adjuvanted vaccines.&lt;ref name=wang/&gt; The alum adjuvant initiates diverse molecular and cellular mechanisms to enhance immunogenicity, including release of proinflammatory cytokines.&lt;ref name=tregoning/&gt;&lt;ref name=wang/&gt; A potential drawback of adjuvanted vaccines is that the virus evolves in a way to avoid the induced vaccine response, making the adjuvant-vaccine technology misdesigned against a changed virus.&lt;ref name=tregoning/&gt; Such a change would require revised manufacturing and increased costs that discourage the routine use of adjuvants.&lt;ref name=tregoning/&gt;&lt;ref name=wang/&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>An April 2020 CEPI report stated: "Strong international coordination and cooperation between vaccine developers, regulators, policymakers, funders, public health bodies and governments will be needed to ensure that promising late-stage vaccine candidates can be manufactured in sufficient quantities and equitably supplied to all affected areas, particularly low-resource regions."&lt;ref name=thanh/&gt; However, some 10% of the public perceives vaccines as unsafe or unnecessary, refusing vaccination{{snd}}a global health threat called [[vaccine hesitancy]]&lt;ref name="who-threat"&gt;{{Cite web |url=https://www.who.int/emergencies/ten-threats-to-global-health-in-2019 |title=Ten health issues WHO will tackle this year |publisher=World Health Organization |access-date=2020-05-26 |year=2019 |archive-url=https://web.archive.org/web/20191111212640/https://www.who.int/emergencies/ten-threats-to-global-health-in-2019 |archive-date=11 November 2019 |url-status=live }}&lt;/ref&gt;{{snd}}which increases the risk of further [[viral shedding|viral spread]] that could lead to COVID‑19 outbreaks.&lt;ref name="dube"&gt;{{Cite journal |last1=Dubé|first1=Eve|last2=Laberge|first2=Caroline|last3=Guay|first3=Maryse|last4=Bramadat|first4=Paul|last5=Roy|first5=Réal|last6=Bettinger|first6=Julie|date=2013-08-01|title=Vaccine hesitancy: an overview|journal=Human Vaccines and Immunotherapeutics|volume=9|issue=8|pages=1763–73|doi=10.4161/hv.24657|issn=2164-554X|pmc=3906279|pmid=23584253| name-list-style = vanc }}&lt;/ref&gt; In mid-2020, estimates from two surveys were that 67% or 80% of people in the U.S. would accept a new vaccination against COVID‑19, with wide disparity by education level, employment status, race, and geography.&lt;ref name="malik"&gt;{{cite journal | last1=Malik | first1=Amyn A | last2=McFadden | first2=SarahAnn M| last3=Elharake | first3=Jad | last4=Omer | first4=Saad B | title=Determinants of COVID-19 vaccine acceptance in the US | journal=EClinicalMedicine, the Lancet | year=2020 | volume=26 | issn=2589-5370 | doi=10.1016/j.eclinm.2020.100495 | page=100495| pmid=32838242 | pmc=7423333 |url=https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(20)30239-X/fulltext| doi-access=free<ins class="diffchange diffchange-inline"> | name-list-style=vanc</ins> }}&lt;/ref&gt;&lt;ref&gt;Linda Thunström, Madison Ashworth, David Finnoff, and Stephen C. Newbold. 2020. Hesitancy towards a COVID‑19 vaccine and prospects for herd immunity. [https://cepr.org/file/9287/download?token=Ba6cin7P ''Covid Economics'' 35]: 7 July 2020&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>The effectiveness of new vaccine is defined by [[Vaccine efficacy|its efficacy]]. An efficacy of less than 60% may result in failure to create [[herd immunity]].&lt;ref name="gates2" /&gt;&lt;ref name="wied" /&gt; Host-("vaccinee")-related determinants that render a person susceptible to infection, such as [[genetics]], health status (underlying disease, nutrition, pregnancy, [[Hypersensitivity|sensitivities]] or [[allergy|allergies]]), [[Immunocompetence|immune competence]], age, and [[Economic impact of the COVID‑19 pandemic|economic impact]] or [[Synthetic psychological environment|cultural environment]] can be primary or secondary factors affecting the severity of infection and response to a vaccine.&lt;ref name="wied" /&gt; Elderly (above age 60), [[Type I hypersensitivity|allergen-hypersensitive]], and [[obesity|obese]] people have susceptibility to compromised [[immunogenicity]], which prevents or inhibits vaccine effectiveness, possibly requiring separate vaccine technologies for these specific populations or repetitive [[Booster dose|booster vaccinations]] to limit [[Transmission (medicine)|virus transmission]].&lt;ref name="wied" /&gt; Further, [[mutation]]s of the virus can alter its structure targeted by the vaccine, thus making the vaccine ineffective.&lt;ref name="zumla"&gt;{{cite journal |first1=Alimuddin | last1=Zumla |first2=David S | last2=Hui |first3=Stanley | last3=Perlman |title=Middle East respiratory syndrome |journal=Lancet |date=2015-09-11 |volume=386 |issue=9997 |pages=995–1007 |doi=10.1016/S0140-6736(15)60454-8 |pmid=26049252 |pmc=4721578 | name-list-style = vanc }}&lt;/ref&gt;&lt;ref name="garcia"&gt;{{cite web |first1=Erin | last1=Garcia de Jesus |title=Is the coronavirus mutating? Yes. But here's why you don't need to panic |url=https://www.sciencenews.org/article/coronavirus-covid19-mutations-strains-variants |publisher=Science News |access-date=21 June 2020 |date=26 May 2020 |archive-url=https://web.archive.org/web/20200621235243/https://www.sciencenews.org/article/coronavirus-covid19-mutations-strains-variants |archive-date=21 June 2020 |url-status=live | name-list-style = vanc }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>Vaccine developers have to invest resources internationally to find enough participants for Phase{{nbsp}}II–III clinical trials when the virus has proved to be a "[[Moving target indication|moving target]]" of changing transmission rate across and within countries, forcing companies to compete for trial participants.&lt;ref name="cohen6-19"&gt;{{cite journal|journal=Science|title=Pandemic vaccines are about to face the real test|volume=368|issue=6497|pages=1295–96|doi=10.1126/science.368.6497.1295|last=Cohen | first=Jon |date=2020-06-19|pmid=32554572|bibcode=2020Sci...368.1295C|url=https://science.sciencemag.org/content/368/6497/1295|doi-access=free|access-date=20 June 2020|archive-url=https://web.archive.org/web/20200621082652/https://science.sciencemag.org/content/368/6497/1295|archive-date=21 June 2020|url-status=live| name-list-style=vanc }}&lt;/ref&gt; As an example in June, the Chinese vaccine developer Sinovac formed alliances in [[Malaysia]], Canada, the UK, and Brazil among its plans to recruit trial participants and manufacture enough vaccine doses for a possible Phase{{nbsp}}III study in Brazil where COVID‑19 transmission was accelerating during June.&lt;ref name=cohen6-19/&gt; As the COVID‑19 pandemic within China became more isolated and controlled, Chinese vaccine developers sought international relationships to conduct advanced human studies in several countries, creating competition for trial participants with other manufacturers and the international Solidarity trial organized by the WHO.&lt;ref name=cohen6-19/&gt; In addition to competition over recruiting participants, clinical trial organizers may encounter  people unwilling to be vaccinated due to [[vaccine hesitancy]]&lt;ref name=dube/&gt; or disbelieving the science of the vaccine technology and its ability to prevent infection.&lt;ref name="howard-cnn"&gt;{{cite news |first1=Jacqueline | last1=Howard |first2=Veronica | last2=Stracqualursi |title=Fauci warns of 'anti-science bias' being a problem in US |url=https://www.cnn.com/2020/06/18/politics/anthony-fauci-coronavirus-anti-science-bias/index.html |access-date=21 June 2020 |work=CNN |date=2020-06-18 |archive-url=https://web.archive.org/web/20200621003117/https://www.cnn.com/2020/06/18/politics/anthony-fauci-coronavirus-anti-science-bias/index.html |archive-date=21 June 2020 |url-status=live | name-list-style = vanc }}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>Having an insufficient number of skilled team members to administer vaccinations may hinder clinical trials that must overcome risks for trial failure, such as recruiting participants in rural or low-density geographic regions, and variations of age, race, ethnicity, or underlying medical conditions.&lt;ref name=cohen6-19/&gt;&lt;ref name="winter"&gt;{{cite journal | last1=Winter | first1=SS | last2=Page-Reeves | first2=JM | last3=Page | first3=KA | last4=Haozous | first4=E | last5=Solares | first5=A | last6=Nicole Cordova | first6=C | last7=Larson | first7=RS | title=Inclusion of special populations in clinical research: important considerations and guidelines|type=Review | journal=Journal of Clinical and Translational Research | volume=4 | issue=1 | date=2018-05-28 | issn=2382-6533 | pmid=30873495 | pmc=6410628 | pages=56–69<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>An effective vaccine for COVID‑19 could save [[trillion]]s of dollars in global economic impact, according to one expert, and would, therefore, make any price tag in the billions look small in comparison.&lt;ref name="gates3"&gt;{{Cite web|title=The first modern pandemic: The scientific advances we need to stop COVID-19|url=https://www.gatesnotes.com/Health/Pandemic-Innovation|last=Gates|first=Bill|date=2020-04-23|publisher=The Gates Notes|access-date=2020-05-06|archive-url=https://web.archive.org/web/20200513122415/https://www.gatesnotes.com/Health/Pandemic-Innovation|archive-date=13 May 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt; It is not yet known if it is possible to create a safe, reliable and affordable vaccine for this virus, and it is not yet known exactly how much the vaccine development will cost.&lt;ref name=gates2/&gt;&lt;ref name=gates1/&gt;&lt;ref name=sanger/&gt; It is possible that billions of dollars could be invested without success.&lt;ref name=reuters/&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>After a vaccine is created, billions of doses will need to be manufactured and distributed worldwide. In April 2020, the Gates Foundation estimated that manufacturing and distribution could cost as much as {{US$|25}}{{nbsp}}billion.&lt;ref&gt;{{Cite news|title=Global philanthropists, experts call for COVID-19 vaccine distribution plan|url=https://www.thestar.com/news/canada/2020/04/30/global-philanthropists-experts-call-for-covid-19-vaccine-distribution-plan.html|date=2020-04-30|first=Mike|last=Blanchfield|work=The Toronto Star|access-date=2020-05-06|archive-url=https://web.archive.org/web/20200507230428/https://www.thestar.com/news/canada/2020/04/30/global-philanthropists-experts-call-for-covid-19-vaccine-distribution-plan.html|archive-date=7 May 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>Different vaccines have different shipping and handling requirements. For example, the Pfizer/BioNTech vaccine BNT162 must be shipped and stored at {{Convert|-70|C|F|abbr=}}, must be used within five days of thawing, and has a minimum order of 975 doses, making it unlikely to be rolled out in settings other than large, well-equipped hospitals.&lt;ref&gt;{{Cite web|date=2020-10-09|title=7 looming questions about the rollout of a Covid-19 vaccine|url=https://www.statnews.com/2020/10/09/7-looming-questions-about-the-rollout-of-a-covid-19-vaccine/|access-date=2020-10-10|website=<ins class="diffchange diffchange-inline">[[Stat (website)|Stat]]</ins>}}&lt;/ref&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>Strategies are being considered for fast-tracking the licensing of a vaccine against COVID‑19, especially by compressing (to a few months) the usually lengthy duration of Phase{{nbsp}}II–III trials (typically many years).&lt;ref name="eyal"&gt;{{Cite journal|last1=Eyal|first1=Nir|last2=Lipsitch|first2=Marc|last3=Smith|first3=Peter G.|title=Human challenge studies to accelerate coronavirus vaccine licensure|url=https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa152/5814216|journal=The Journal of Infectious Diseases|doi=10.1093/infdis/jiaa152|date=31 March 2020|volume=221|issue=11|pages=1752–56|pmid=32232474|pmc=7184325|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200424095527/https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa152/5814216|archive-date=24 April 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;&lt;ref name="callaway"&gt;{{Cite journal|vauthors=Callaway E|date=April 2020|title=Should scientists infect healthy people with the coronavirus to test vaccines?|url=https://www.nature.com/articles/d41586-020-00927-3|journal=Nature|volume=580|issue=7801|page=17|doi=10.1038/d41586-020-00927-3|pmid=32218549|bibcode=2020Natur.580...17C|doi-access=free|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200414035045/https://www.nature.com/articles/d41586-020-00927-3|archive-date=14 April 2020|url-status=live<ins class="diffchange diffchange-inline"> | name-list-style=vanc </ins>}}&lt;/ref&gt;&lt;ref name="boodman"&gt;{{Cite web|url=https://www.statnews.com/2020/03/11/researchers-rush-to-start-moderna-coronavirus-vaccine-trial-without-usual-animal-testing/|title=Coronavirus vaccine clinical trial starting without usual animal data|<ins class="diffchange diffchange-inline">work</ins>=<ins class="diffchange diffchange-inline">[[Stat (website)|Stat]]</ins>|first=Eric | last=Boodman |date=13 March 2020|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200417060301/https://www.statnews.com/2020/03/11/researchers-rush-to-start-moderna-coronavirus-vaccine-trial-without-usual-animal-testing/|archive-date=17 April 2020|url-status=live| name-list-style=vanc }}&lt;/ref&gt; [[Human challenge study|Challenge studies]] have been implemented previously for diseases less deadly than COVID‑19 infection, such as common influenza, [[typhoid fever]], [[cholera]], and [[malaria]].&lt;ref name=callaway/&gt;&lt;ref name=cohen/&gt; Following preliminary proof of safety and efficacy of a candidate vaccine in laboratory animals and healthy humans, controlled challenge studies might be implemented to bypass typical Phase{{nbsp}}III research, providing an accelerated path to license a COVID‑19 vaccine.&lt;ref name="eyal" /&gt;&lt;ref name="cohen"&gt;{{Cite journal|url=https://www.sciencemag.org/news/2020/03/speed-coronavirus-vaccine-testing-deliberately-infecting-volunteers-not-so-fast-some|title=Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn|last=Cohen|first=Jon|date=31 March 2020|journal=Science|doi=10.1126/science.abc0006|access-date=19 April 2020|archive-url=https://web.archive.org/web/20200414031310/https://www.sciencemag.org/news/2020/03/speed-coronavirus-vaccine-testing-deliberately-infecting-volunteers-not-so-fast-some|archive-date=14 April 2020|url-status=live | name-list-style = vanc }}&lt;/ref&gt;&lt;ref name=callaway/&gt; Beginning in January 2021, dozens of young adult volunteers will be deliberately infected with COVID‑19 in a challenge trial conducted in a [[London, England|London]] hospital under management by the UK government COVID-19 Vaccine Taskforce.&lt;ref name="call-challenge"&gt;{{cite journal |author1=Ewen Callaway |title=Dozens to be deliberately infected with coronavirus in UK 'human challenge' trials |journal=Nature |date=20 October 2020 |doi=10.1038/d41586-020-02821-4 |url=https://www.nature.com/articles/d41586-020-02821-4}}&lt;/ref&gt; Once an infection dose of COVID‑19 is identified, two or more of the candidate COVID-19 vaccines will be tested for effectiveness in preventing infection.&lt;ref name=call-challenge/&gt; </div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:40
ID: 985486563
FULLTEXT: <td class="diff-addedline"><div>By June 2020, tens of billions of dollars were invested by corporations, governments, international health organizations, and university research groups to develop dozens of vaccine candidates and prepare for global vaccination programs to immunize against COVID‑19 infection.&lt;ref name=gates1/&gt;&lt;ref name="hbr"&gt;{{Cite news|last1=Weintraub|first1=Rebecca|last2=Yadav|first2=Prashant|last3=Berkley|first3=Seth|date=2020-04-02|title=A COVID-19 vaccine will need equitable, global distribution|journal=Harvard Business Review|url=https://hbr.org/2020/04/a-covid-19-vaccine-will-need-equitable-global-distribution|access-date=2020-06-09|issn=0017-8012|archive-url=https://web.archive.org/web/20200609173105/https://hbr.org/2020/04/a-covid-19-vaccine-will-need-equitable-global-distribution|archive-date=9 June 2020|url-status=live | name-list-style = vanc }}&lt;/ref&gt;&lt;ref name="cbcr"&gt;{{Cite news|date=2020-05-08|title=COVID-19 pandemic reveals the risks of relying on private sector for life-saving vaccines, says expert|work=CBC Radio|url=https://www.cbc.ca/radio/thesundayedition/the-sunday-edition-for-may-10-2020-1.5554451/covid-19-pandemic-reveals-the-risks-of-relying-on-private-sector-for-life-saving-vaccines-says-expert-1.5554463|url-status=live|access-date=2020-06-08|archive-url=https://web.archive.org/web/20200513172525/https://www.cbc.ca/radio/thesundayedition/the-sunday-edition-for-may-10-2020-1.5554451/covid-19-pandemic-reveals-the-risks-of-relying-on-private-sector-for-life-saving-vaccines-says-expert-1.5554463|archive-date=13 May 2020}}&lt;/ref&gt;&lt;ref name="ahmed"&gt;{{Cite web|last=Ahmed|first=Darius D.|date=2020-06-04|title=Oxford, AstraZeneca COVID-19 deal reinforces 'vaccine sovereignty'|url=https://www.statnews.com/2020/06/04/oxford-astrazeneca-covid-19-deal-reinforces-vaccine-sovereignty/|access-date=2020-06-08|<ins class="diffchange diffchange-inline">work</ins>=<ins class="diffchange diffchange-inline">[[Stat (website)|Stat]]</ins>|archive-url=https://web.archive.org/web/20200612125335/https://www.statnews.com/2020/06/04/oxford-astrazeneca-covid-19-deal-reinforces-vaccine-sovereignty/|archive-date=12 June 2020|url-status=live | name-list-style = vanc }}&lt;/ref&gt; The corporate investment and need to generate value for public shareholders raised concerns about a "market-based approach" in vaccine development, costly pricing of eventual licensed vaccines, preferred access for distribution first to affluent countries, and sparse or no distribution to where the pandemic is most aggressive, as predicted for densely-populated, impoverished countries unable to afford vaccinations.&lt;ref name=gates1/&gt;&lt;ref name=sanger/&gt;&lt;ref name=cbcr/&gt; The collaboration of the University of Oxford with AstraZeneca (a global pharmaceutical company based in the UK) raised concerns about price and sharing of eventual profits from international vaccine sales, arising from whether the UK government and university as public partners had commercialization rights.&lt;ref name=ahmed/&gt; AstraZeneca stated that initial pricing of its vaccine would not include a [[profit margin]] for the company while the pandemic was still expanding.&lt;ref name=ahmed/&gt;</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486563
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486563&oldid=985484532


PRE
Title: COVID-19 vaccine
Date: 27/10/2020 00:03:45
ID: 985486592
FULLTEXT: <td class="diff-addedline"><div>* {{cite web | last=Levine | first=Hallie | title=The 5 Stages of COVID-19 Vaccine Development: What You Need to Know About How a Clinical Trial Works | website=Johnson &amp; Johnson | date=23 September 2020 | url=https://www.jnj.com/innovation/the-5-stages-of-covid-19-vaccine-development-what-you-need-to-know-about-how-a-clinical-trial-works }}</div></td>
Current Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985505141&oldid=985486592
Previous Link: https://en.wikipedia.org//w/index.php?title=COVID-19_vaccine&diff=985486592&oldid=985486563


